77123-55-8

Usage

Uses

Used in Organic Synthesis:
3-(TRIMETHYLSILYL)ETHYNYLBENZALDEHYDE is used as a reagent in organic synthesis for its ability to participate in a wide range of chemical reactions, facilitating the formation of complex organic molecules.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 3-(TRIMETHYLSILYL)ETHYNYLBENZALDEHYDE is used as a key intermediate in the synthesis of heterocyclic compounds, which are often found in medicinally relevant molecules, contributing to the development of new drugs.
Used in Agrochemical Synthesis:
Similarly, in agrochemical applications, 3-(TRIMETHYLSILYL)ETHYNYLBENZALDEHYDE serves as a precursor in the synthesis of heterocyclic compounds that can be used in the development of pesticides and other agricultural chemicals.
Used in Protection and Deprotection of Functional Groups:
The trimethylsilyl group in 3-(TRIMETHYLSILYL)ETHYNYLBENZALDEHYDE can be easily removed under mild conditions, making it an effective agent for the protection and deprotection of functional groups in organic synthesis, which is crucial for the selective modification of complex molecules.

InChI:InChI=1/C16H17ClN2O3S2/c17-15-14(11-20)23-16(19(15)12-7-3-1-4-8-12)18-24(21,22)13-9-5-2-6-10-13/h2,5-6,9-12H,1,3-4,7-8H2

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 1066-54-2 trimethylsilylacetylene 
• 696-41-3 m-iodobenzaldehyde 
• 3989-13-7 2-(3-bromophenyl)ethynyltrimethylsilane 
• 68-12-2 N,N-dimethyl-formamide 
• 3375-31-3 palladium diacetate 

Downstream Products

• 77123-56-9 3-ethynylbenzaldehyde 
• 372969-91-0 2-(3-ethynylphenyl)-4,5-dihydro-1,3-dithiole 
• 87787-95-9 5,5'-(hexafluoroisopropylidene)bis[1-phenyl-2-(3-ethynylphenyl)benzimidazole] 

Relevant academic research and scientific papers

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Structural Basis for Genetic-Code Expansion with Bulky Lysine Derivatives by an Engineered Pyrrolysyl-tRNA Synthetase

Yanagisawa et al. analyzed the Y306A/Y384F mutant of Methanosarcina mazei pyrrolysyl-tRNA synthetase (PylRS) with 17 non-natural, bulky oxycarbonyllysine derivatives for tRNAPyl aminoacylation and site-specific incorporation into proteins. Fourteen crystal structures of the amino acid-bound PylRS mutant revealed the structural bases of the binding. This information facilitates the structure-based design of novel amino acids. Pyrrolysyl-tRNA synthetase (PylRS) and tRNAPyl have been extensively used for genetic-code expansion. A Methanosarcina mazei PylRS mutant bearing the Y306A and Y384F mutations (PylRS(Y306A/Y384F)) encodes various bulky non-natural lysine derivatives by UAG. In this study, we examined how PylRS(Y306A/Y384F) recognizes many amino acids. Among 17 non-natural lysine derivatives, N?-(benzyloxycarbonyl)lysine (ZLys) and 10 ortho/meta/para-substituted ZLys derivatives were efficiently ligated to tRNAPyl and were incorporated into proteins by PylRS(Y306A/Y384F). We determined crystal structures of 14 non-natural lysine derivatives bound to the PylRS(Y306A/Y384F) catalytic fragment. The meta- and para-substituted ZLys derivatives are snugly accommodated in the productive mode. In contrast, ZLys and the unsubstituted or ortho-substituted ZLys derivatives exhibited an alternative binding mode in addition to the productive mode. PylRS(Y306A/Y384F) displayed a high aminoacylation rate for ZLys, indicating that the double-binding mode minimally affects aminoacylation. These precise substrate recognition mechanisms by PylRS(Y306A/Y384F) may facilitate the structure-based design of novel non-natural amino acids.

Organocatalysis by a multidentate halogen-bond donor: An alternative to hydrogen-bond based catalysis

A charge neutral iodoethynyl-based multidentate halogen-bond donor was synthesized and successfully utilized as an organocatalyst in a benchmark Ritter-type solvolysis reaction. The catalytic activity was monitored using 1H NMR spectroscopy and

Discovery of 2,4-dimethoxypyridines as novel autophagy inhibitors

Autophagy is a catabolic process, which mediates degradation of cellular components and has important roles in health and disease. Therefore, small molecule modulators of autophagy are in great demand. Herein, we describe a phenotypic high-content screen for autophagy inhibitors, which led to the discovery of a dimethoxypyridine-based class of autophagy inhibitors, which derive from previously reported, natural product-inspired MAP4K4 inhibitors. Comprehensive structure-activity relationship studies led to a potent compound, and biological validation experiments indicated that the mode of action was upstream or independent of mTOR.

GPR40 agonist and its application

The invention provides a novel benzyne compound and its stereisomer, salt, hydrate or crystal for adjusting G protein coupled receptor 40 (GPR40) functions and especially for preventing or treating diabetes. The invention also provides a useful intermedia

Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole

GPR40 is an attractive target due to its glucose-stimulated insulin secretion effect with low risk of causing hypoglycemia, which also can be seen from the clinical studies using TAK-875 (fasiglifam). In the present studies, we discovered a series of anal

A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities

Inhibition of the enzymatic activity of histone deacetylase (HDAC) is a promising therapeutic strategy for cancer treatment and several distinct small molecule histone deacetylase inhibitors (HDACi) have been reported. We have previously identified a new class of non-peptide macrocyclic HDACi derived from 14- and 15-membered macrolide skeletons. In these HDACi, the macrocyclic ring is linked to the zinc chelating hydroxamate moiety through a para-substituted aryl-triazole cap group. To further delineate the depth of the SAR of this class of HDACi, we have synthesized series of analogous compounds and investigated the influence of various substitution patterns on their HDAC inhibitory, anti-proliferative and anti-inflammatory activities. We identified compounds 25b and 38f with robust anti-proliferative activities and compound 26f (IC50 47.2 nM) with superior anti-inflammatory (IC50 88 nM) activity relative to SAHA.

A one-pot allylation-hydrostannation sequence with recycling of the intermediate tin waste

A one-pot allylation and hydrostannation of alkynals where the tin byproduct formed in the first step of the reaction is recycled and used in the second step of the sequence is presented. Specifically, a BF3· OEt2-promoted allylstannation of the aldehyde moiety in the alkynal is followed by the introduction of polymethylhydrosiloxane (PMHS) and catalytic B(C6F5)3, which convert the tin byproduct of the allylation into Bu3SnH, which then hydrostannates the alkyne in the molecule. 119Sn and 11B NMR data suggest an organotin fluoride species is formed during the allylation step and involved in the tin recycling step.

From trigonal bipyramidal to platonic solids: Self-assembly and self-sorting study of terpyridine-based 3d architectures

Using a series of tritopic 2,2':6',2'-terpyridine (tpy) ligands constructed on adamantane, three discrete 3D metallo-supramolecular architectures were assembled, i.e., trigonal bipyramidal, tetrahedron, and cube. The self-assembly used tritopic ligands as

Synthesis and characterization of redox-active mononuclear Fe(κ2-dppe)(η5-C5Me 5)-Terminated π-conjugated wires

Several new redox-active Fe(κ2-dppe)(η5- C5Me5) arylacetylide complexes featuring pendant ethynyl (Fe(κ2-dppe)(η5-C5Me 5)[{Ci -C(1,4-C6H4)}n